Evaluation of usage patterns and user perception of the drug–drug interaction database SFINX

Abstract

PurposeThe aim of the present study was to investigate how prescribers and pharmacists use and perceive the drug-drug interaction database SFINX in their clinical work. MethodsA questionnaire was developed with questions aimed at the usage of SFINX, and the perceptions of the database. The questionnaire was sent out to all registered users of the web application of SFINX.The anonymous answers from the target users, prescribers and pharmacists were summarized using descriptive statistics. Statistical analysis was performed on age and gender differences for some questions regarding different usage patterns. ResultsThe questionnaire was sent to 11 763 registered SFINX users. The response rate was 23 %, including 1871 answers from prescribers or pharmacists. SFINX was reported to be used at least weekly or more often by 45% of the prescribers and 51% of the pharmacists. Many prescribers reported using the database during the patient consultation (60%) or directly before or after (56%). Among the prescribers, 74% reported that the information received made them change their action at least sometimes. About 20% of the prescribers and 25% of the pharmacists considered the information as irrelevant sometimes or more often. ConclusionMost prescribers and pharmacists reported using SFINX in direct association with a patient consultation. Information received by using SFINX makes prescribers and pharmacists change their handling of patients. DDI databases with relevant information about patient handling might improve drug treatment outcome.

Polypharmacy in chronic diseases–Reduction of Inappropriate Medication and Adverse drug events in older populations by electronic Decision Support (PRIMA-eDS): study protocol for a randomized controlled trial

“…Databases on drug-drug interactions and renal dosing developed by Medbase Ltd. have been included in EBMeDS. The design and usability of these databases have been described [31, 37, 38], and their impact evaluated [39, 40]. Because of its modular design, comprehensiveness and easy integration with EHRs and case-report forms, EBMeDS was selected as the platform for developing the PRIMA-eDS tool.…”

A concise drug alerting rule set for Chinese hospitals and its application in computerized physician order entry (CPOE)

“…However, it’s better to design more DDI sub-types in order to achieve more fine-grained alerts. For example, the SFINX project (Andersson et al 2015) tiers DDIs according to clinical significance (A–D), which enables fine-grained threshold settings for automated warnings.Lack of complete evaluation. In this study, the accept and override rates can be easily calculated from the log data.…”

“…Classen et al (2011) identified 7 most common DDIs by reviewing multiple sources. The public DDI knowledge base SFINX (Swedish, Finnish, INteraction X-referencing) tiers DDIs according to clinical significance (A-D), which enables threshold settings for automated warnings (Andersson et al 2015). …”

Implementing an evidence-based computerized decision support system linked to electronic health records to improve care for cancer patients: the ONCO-CODES study protocol for a randomized controlled trial

“…Moreover, the CDSS provides information about more than 10,000 drug–drug interactions or other drug-related problems, giving advice on how to handle them [34]. For instance, in a diabetic patient, a diagnosis of renal failure, or a laboratory result of creatinine increase, can trigger an alert message to reduce the drug dosage (e.g., cisplatin) based on the patient’s glomerular filtration rate (GFR).There are also several reminders that may help oncologists in the holistic care of the patient.…”